Details for New Drug Application (NDA): 020191
✉ Email this page to a colleague
The generic ingredient in ALOMIDE is lodoxamide tromethamine. One supplier is listed for this compound. Additional details are available on the lodoxamide tromethamine profile page.
Summary for 020191
Tradename: | ALOMIDE |
Applicant: | Novartis |
Ingredient: | lodoxamide tromethamine |
Patents: | 0 |
Pharmacology for NDA: 020191
Physiological Effect | Decreased Histamine Release |
Suppliers and Packaging for NDA: 020191
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ALOMIDE | lodoxamide tromethamine | SOLUTION/DROPS;OPHTHALMIC | 020191 | NDA | Novartis Pharmaceuticals Corporation | 0078-0736 | 0078-0736-10 | 1 BOTTLE in 1 CARTON (0078-0736-10) / 10 mL in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | EQ 0.1% BASE | ||||
Approval Date: | Sep 23, 1993 | TE: | RLD: | Yes |
Expired US Patents for NDA 020191
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | ALOMIDE | lodoxamide tromethamine | SOLUTION/DROPS;OPHTHALMIC | 020191-001 | Sep 23, 1993 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription